Novagali eye Treatment for Vernal Keratoconjunctivitis (VKC) Successful in Phase III Trial
Tuesday, April 10th, 2007Israeli-French drug development company Novagali SA, which was founded on the basis of research conducted by Prof. Simon Benita of the Hebrew University of Jerusalem, has successfully completed European Medicines Agency (EMEA) Phase III clinical trials of its eye treatment for Vernal Keratoconjunctivitis (VKC)..
































